Global Neurodegenerative Disease Market by Drug Class

Global Neurodegenerative Disease Market by Application
Global Neurodegenerative Disease Market by Region
North America
Asia Pacific
Latin America
Middle East & Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neurodegenerative Disease Market Snapshot
Chapter 4. Global Neurodegenerative Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. By Drug Class & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Class:
5.2.1. NMDA
5.2.2. SSRIs
5.2.3. Decarboxylase inhibitors
5.2.4. Cholinesterase Inhibitors
5.2.5. Immunomodulators
5.2.6. Dopamine Inhibitors
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. By Application & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
6.2.1. Parkinson’s Disease
6.2.2. Huntington Disease
6.2.3. Amyotrophic Lateral Sclerosis
6.2.4. Alzheimer’s Disease
Chapter 7. Neurodegenerative Disease Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Neurodegenerative Disease Market revenue (US$ Million) estimates and forecasts By Drug Class, 2021 - 2034
7.1.2. North America Neurodegenerative Disease Market revenue (US$ Million) estimates and forecasts By Application, 2021 - 2034
7.1.3. North America Neurodegenerative Disease Market revenue (US$ Million) estimates and forecasts by country, 2021 - 2034
7.2. Europe
7.2.1. Europe Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, 2021 - 2034
7.2.2. Europe Neurodegenerative Disease Market revenue (US$ Million) By Application, 2021 - 2034
7.2.3. Europe Neurodegenerative Disease Market revenue (US$ Million) by country, 2021 - 2034
7.3. Asia Pacific
7.3.1. Asia Pacific Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, 2021 - 2034
7.3.2. Asia Pacific Neurodegenerative Disease Market revenue (US$ Million) By Application, 2021 - 2034
7.3.3. Asia Pacific Neurodegenerative Disease Market revenue (US$ Million) by country, 2021 - 2034
7.4. Latin America
7.4.1. Latin America Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, (US$ Million)
7.4.2. Latin America Neurodegenerative Disease Market revenue (US$ Million) By Application, (US$ Million)
7.4.3. Latin America Neurodegenerative Disease Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, (US$ Million)
7.5.2. Middle East & Africa Neurodegenerative Disease Market revenue (US$ Million) By Application, (US$ Million)
7.5.3. Middle East & Africa Neurodegenerative Disease Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Novartis
8.2.2. Pfizer
8.2.3. Merck Serono
8.2.4. Biogen Idec
8.2.5. TEVA
8.2.6. UCB
8.2.7. Boehringer Ingelheim
8.2.8. Sanofi
8.2.9. GlaxoSmithKline
8.2.10. Other Key Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.